Bromocriptine for the treatment of postoperative cerebellar mutism syndrome in pediatric patients: Three case reports.
J Oncol Pharm Pract
; 27(7): 1753-1757, 2021 Oct.
Article
em En
| MEDLINE
| ID: mdl-33356885
ABSTRACT
INTRODUCTION:
Cerebellar mutism syndrome (CMS) is a common complication after posterior fossa tumor resection. It is characterized by a significant lack or loss of speech. Its biological origin remains unclear and there are no standardized treatments. However, bromocriptine seems to be a possible treatment for this condition. CASE REPORT In this paper, we present three cases of pediatric patients (4, 5, and 17-year old) who developed CMS after posterior fossa tumor surgery. They were treated with bromocriptine to improve neurological symptoms.Management andoutcome:
Bromocriptine was started at a low dose and was progressively increased to reach the minimum effective dose. After four months of treatment, a normal and fluid speech was observed in the three patients. No discontinuation due to adverse events were reported.DISCUSSION:
Bromocriptine has shown to be an effective and safe treatment for CMS in pediatric patients after posterior fossa tumor resection.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Infratentoriais
/
Neoplasias Cerebelares
/
Meduloblastoma
/
Mutismo
Tipo de estudo:
Etiology_studies
Limite:
Child
/
Humans
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article